Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2005
12/14/2005EP1603898A2 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent
12/14/2005EP1603897A1 Pyrazole compounds useful in the treatment of inflammation
12/14/2005EP1603594A1 Pharmaceutical compositions of cell lysate and processes for the production and use thereof
12/14/2005EP1603593A2 Pharmaceutical composition
12/14/2005EP1603575A2 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
12/14/2005EP1603570A2 Aminoheteroaryl compounds as protein kinase inhibitors
12/14/2005EP1603561A2 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor
12/14/2005EP1603552A1 Carnitine retention
12/14/2005EP1603548A2 Method and composition for treating neurodegenerative disorders
12/14/2005EP1603547A1 Trospium containing compositions
12/14/2005EP1603545A2 Method of treatment of disease using an adenosine a1 receptor antagonist
12/14/2005EP1603544A1 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo 2.2.1 heptan-2-amine
12/14/2005EP1603542A1 Treatment and/or prevention of non-viral epithelial damage
12/14/2005EP1603537A2 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
12/14/2005EP1603530A1 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
12/14/2005EP1603499A2 Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
12/14/2005EP1603409A2 Salutary compositions consisting of fungi containing lipids and thiocyanates
12/14/2005EP1527084A4 Promoters exhibiting endothelial cell specificity and methods of using same
12/14/2005EP1439847A4 Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
12/14/2005EP1405074A4 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/14/2005EP1370144A4 Noninvasive measurements of chemical substances
12/14/2005EP1326858B1 Piperidine compounds as anti-allergic
12/14/2005EP1280904B1 Pain signaling molecules
12/14/2005EP1274430B1 Cabergoline for the treatment of fibromyalgia and chronic fatigue syndrome
12/14/2005EP1267803B1 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins
12/14/2005EP1255870B1 5-hydroxytryptamine transporter gene polymorphisms
12/14/2005EP1178821B1 Use of anti-hbp antibodies in the inhibition of bradykinin release
12/14/2005EP1114160B1 Moraxella catarrhalis basb034 polypeptides and uses thereof
12/14/2005EP1007714B1 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
12/14/2005EP0970198B1 Micro-organisms with increased production of clavulanic acid
12/14/2005EP0956036B1 Anti-fibrotic agent assay
12/14/2005CN1708319A Pharmaceutical composition comprising a CDK inhibitor and gemcitabine
12/14/2005CN1708318A Remedy for corneal failure
12/14/2005CN1708302A Pharmacological treatment for sleep apnea
12/14/2005CN1708297A Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
12/14/2005CN1708296A Combinations of anti-cancer agents
12/14/2005CN1708293A S1p receptor agonist for treating demyelinate disease
12/14/2005CN1706498A Active carbon antiseptic
12/14/2005CN1231762C Method for directly identifying candidate compound
12/14/2005CN1231467C High affinity ligands for nociceptin receptor ORL-1
12/14/2005CN1231459C Novel aminobenzophenones
12/13/2005US6974838 dopamine reuptake inhibitors; for treatment of thoratic outlet obstruction syndrome
12/13/2005US6974837 Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
12/13/2005US6974828 3-((2-((3-((Amino(imino)methyl)amino)benzoyl)amino)phenyl)sulf anyl)- 3-(3-pyridinyl)propanoic acid, for example; angiogenic inhibitors; antitumor, -carcinogenic, -metastatic, -diabetic, -arthritic and inflammatory agents; bone disorders
12/13/2005US6974823 Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
12/13/2005US6974821 Methods for treating neuropsychiatric disorders
12/13/2005US6974818 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
12/13/2005US6974807 administering topically to alleviate proliferative skin diease; nontoxic
12/13/2005US6974800 Formulations comprising an inhibitor of carboxypeptidase U and A thrombin inhibitor
12/13/2005US6974796 Therapeutic compositions for treatment of a damaged tissue
12/13/2005US6974791 These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium.
12/13/2005US6974697 Composition for use in the generation and culturing of skin
12/13/2005US6974596 Comprising cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol; antiallergic agents and atopic dermatitis preventives
12/13/2005US6974594 Method of preparing biological materials and preparations produced using same
12/13/2005US6974591 Suspending a pore-forming agent in an aqueous dispersion of a film-forming, water insoluble polymer to form a coating suspension having solid particles of pore former suspended therein, and coating a drug-containing solid core, drying
12/13/2005US6974583 Used to prevent or combat the harmful effects of UV and/or pollution on the skin, loss of firmness and/or elasticity of the skin, etc.
12/13/2005US6974568 Treatment for cough
12/13/2005CA2435729C New film coating
12/13/2005CA2314571C Methods and compositions for treating diseases and conditions of the eye
12/13/2005CA2278521C Two phase skin preparations comprising lipophilic and hydrophilic components
12/11/2005CA2467769A1 Methods and formulations for testosterone suppression
12/10/2005CA2507847A1 Prostaglandin reductase
12/10/2005CA2507738A1 Modulation of peroxisome proliferator-activated receptors
12/08/2005WO2005116253A1 Probe for diagnosis of marfan’s syndrome and method of screening with the probe
12/08/2005WO2005115472A2 Compositions comprising gamma-linolenic acid and iodine for improving breast health in women
12/08/2005WO2005115471A2 Methods and compositions for treatment of nicotine dependence and dementias
12/08/2005WO2005115470A2 PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
12/08/2005WO2005115469A2 Estrogen modulation of ifn-gamma-mediated conditions and diseases
12/08/2005WO2005115468A1 Novel drug discovery target and medicine acting on the same
12/08/2005WO2005115467A1 Combinations comprising antimuscarinic agents and beta-adrenergic agonists
12/08/2005WO2005115466A1 Combinations comprising antimuscarinic agents and corticosteroids
12/08/2005WO2005115465A1 Combinations comprising antimuscarinic agents and pde4 inhibitors
12/08/2005WO2005115464A1 Combinations comprising antimuscarinic agents and corticosteroids
12/08/2005WO2005115463A1 Combinations comprising antimuscarinic agents and beta-adrenergic agonists
12/08/2005WO2005115462A1 Combinations comprising antimuscarinic agents and pde4 inhibitors
12/08/2005WO2005115461A2 Pharmaceutical composition for modulating the activity of triglyceride hydrolase
12/08/2005WO2005115455A2 Methods and reagents for the treatment of immunoinflammatory disorders
12/08/2005WO2005115417A2 Polycationic antimicrobial therapeutic
12/08/2005WO2005115411A1 Agent for visualizing transparent tissue
12/08/2005WO2005115359A2 Methods and compositions for the treatment of uveitis
12/08/2005WO2005115170A1 Oral and /or topical compositions
12/08/2005WO2005099713A3 Novel antiviral pharmaceutical composition
12/08/2005WO2005089751A3 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous inflammation
12/08/2005WO2005074925A8 Compositions substantially free of galactomannan containing piperacillin and tazobactam
12/08/2005WO2005070461A3 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
12/08/2005WO2005065308A3 Compositions and methods to treat recurrent medical conditions
12/08/2005WO2005059172A3 Method and nucleic acids for the improved treatment of breast cell proliferative disorders
12/08/2005WO2005058341A3 Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
12/08/2005WO2005053725A3 Cancer treatment
12/08/2005WO2005046797B1 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
12/08/2005WO2005046726A3 Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
12/08/2005WO2005011580A3 Compositions and methods for herpes simplex prophylaxis and treatment
12/08/2005WO2003060148A3 Androgen regulated nucleic acid molecules and encoded proteins
12/08/2005WO2003032895A3 Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
12/08/2005WO2002057256A9 Piperazinylcarbonylquinolines and -isoquinolines
12/08/2005US20050272815 Compounds and compositions for delivering active agents
12/08/2005US20050272804 Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
12/08/2005US20050272801 Isoprenoid pathway inhibitors for stimulating cartilage growth
12/08/2005US20050272799 Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
12/08/2005US20050272789 Triazole-derived kinase inhibitors and uses thereof
1 ... 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 ... 1151